What are the key learnings from the 7-year follow-up of PARTNER 3?
Listen to this PCR London Valves 2025 interview with Philippe Généreux and Philippe Pibarot, who explore the 7-year results of PARTNER 3 in low-risk patients.
They walk through the main findings of this TAVR versus SAVR comparison in symptomatic severe aortic stenosis (AS). At 7 years, the primary endpoint — the composite of mortality, stroke and rehospitalisation — shows similar rates between both strategies.
The conversation then turns to valve durability and whether the early promises of TAVR are being fulfilled when compared with surgery, what still needs to be improved on each side, and…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.